Third Annual TCGC: The Clinical Genome Conference, San Francisco, June 10-12, 2014 by Bio-IT World and Cambridge Healthtech Institute
Reporter: Aviva Lev-Ari, PhD, RN
UPDATED on 5/1/2014
Register by May 2 for
Hotel Kabuki, San Francisco, CA
June 10 – 12, 2014
FINAL AGENDA
CLINICAL GENOME
conference
THE 3rd ANNUAL
Mining the Genome for Medicine Clinical Genome Conference.com
TCGC
The unstoppable march of genomics into clinical practice continues. In an ideal world, the expanding use of genomic tools will identify disease before the onset of clinical symptoms and determine individualized drug treatment leading to precision medicine. However, many challenges remain or the successful translation of genomic knowledge and technologies into health advances and actionable patient care. Join vital discussions of the applications, questions and solutions surrounding clinical genome analysis.
KEYNOTE SPEAKERS
Atul Butte, M.D., Ph.D.
Division Chief and Associate Professor, Stanford University School of Medicine; Director, Center for Pediatric Bioinformatics, Lucile Packard Children’s Hospital
David Galas, Ph.D.
Principal Scientist, Pacific Northwest Diabetes Research Institute
Gail P. Jarvik, M.D., Ph.D.
Head, Division of Medical Genetics, Arno G. Motulsky Endowed Chair in Medicine and Professor, Medicine and Genome Sciences, University of Washington Medical Center
John Pfeifer, M.D., Ph.D.
Vice Chair, Clinical Affairs, Pathology and Immunology; Professor, Pathology and Immunology, Washington University
John Quackenbush, Ph.D.
Professor, Dana-Farber Cancer Institute and Harvard School of Public Health; Co-Founder and CEO, GenoSpace
Topics Include:
• Working with the Payer Process
• Genome Variation and Clinical Utility
• NGS Is Guiding Therapies
• NGS Is Redefining Genomics
• Interpretation and Translation to the Client
• Integrating Genomic Data into the Clinic
ClinicalGenomeConference.com
Cambridge Healthtech Institute
250 First Avenue, Suite 300
Needham, MA 02494
www.healthtech.com
TUESDAY, JUNE 10
7:30 am Conference Registration and Morning Coffee
Working with the Payer Process
8:30 Chairperson’s Opening Remarks
»»KEYNOTE PRESENTATION
8:45 Case Study on Working through the Payer Process
John Pfeifer, M.D., Ph.D., Vice Chair, Clinical Affairs, Pathology; Professor,
Pathology and Immunology; Professor, Obstetrics and Gynecology, Washington
University School of Medicine
If next-generation sequencing (NGS) is to become a part of patient care in routine clinical practice (whether in the setting of oncology or in the setting of inherited genetic disorders), labs that perform clinical NGS must be reimbursed for the testing they provide. Genomics and Pathology Services at Washington University in St. Louis (GPS@WUSTL) will be used as a case study of a national reference lab that has been successful in achieving high levels of reimbursement for the clinical NGS testing it performs, including from private payers. The reasons for GPS’s success will be discussed, including NGS test design, clinical focus of testing, use of different models for reimbursement and payer education.
9:30 Implementation of Clinical Cancer Genomics within an Integrated
Healthcare System
Lincoln D. Nadauld, M.D., Ph.D., Director, Cancer Genomics, Intermountain Healthcare
Precision cancer medicine involves the detection of tumor-specific DNA alterations followed by treatment with therapeutics that specifically target the actionable mutations. Significant advances in genomic technologies have now rendered extended genomic analyses of human malignancies technologically and financially feasible for clinical adoption. Intermountain Healthcare, an integrated healthcare delivery system, is taking advantage of these advances to programmatically implement genomics into the regular treatment of cancer patients to improve clinical outcomes and reduce treatment costs.
10:00 PANEL DISCUSSION:
Payer’s Dilemma: Evolution vs. Revolution
As falling genome sequencing costs help clinicians refine patient diagnoses and therapeutic approaches, new complexities arise over insurance coverage of such tests, classification by CPT codes and other reimbursement issues. Experts on this panel will discuss payer challenges and changes—both rapid and gradual—occurring alongside these advances in clinical genomics.
Moderator: Katherine Tynan, Ph.D., Business Development & Strategic Consulting for Diagnostics
Companies, Tynan Consulting LLC
Panelists:
Tonya Dowd, MPH, Director, Reimbursement Policy and Market Access, Quorum Consulting
Mike M. Moradian, Ph.D., Director of Operations and Molecular Genetics Scientist, Kaiser
Permanente Southern California Regional Genetics Laboratory
Rina Wolf, Vice President of Commercialization Strategies, Consulting and Industry Affairs, XIFIN
Additional Panelists to be Announced
10:45 Networking Coffee Break
11:15 Beyond Genomics: Preparing for the Avalanche of Post-Genomic
Clinical Findings
Jimmy Lin, M.D., Ph.D., President, Rare Genomics Institute
Whole genomic and exomics sequencing applied clinically is revealing newly discovered genes and syndromes at an astonishing rate. While clinical databases and variant annotation continue to grow, much of the effort needed is functional analysis and clinical correlation. At RGI, we are building a comprehensive functional genomics platform that includes electronic health records, biobanking, data management, scientific idea crowdsourcing and contract research sourcing.
11:45 The MMRF CoMMpass Clinical Trial: A Longitudinal Observational
Trial to Identify Genomic Predictors of Outcome in Multiple Myeloma
Jonathan J. Keats, Ph.D., Assistant Professor, Integrated Cancer Genomics Division, Translational
Genomics Research Institute
12:15 pm Luncheon Presentation: Sponsored by
Big Data & Little Data – From Patient Stratification
to Precision Medicine
Colin Williams, Ph.D., Director, Product Strategy, Thomson Reuters
Molecular data has the power, when unlocked, to transform our understanding of disease to support drug discovery and patient care. The key to unlocking this potential is ‘humanising’ the data, through tools and techniques, to a level that supports interpretation by Life Science professionals. This talk will focus on strategies for extracting insight from ‘big data’ by shrinking it to ‘little data’, with a focus on applications to support patient stratification in drug discovery and for practising precision medicine in a clinical setting.
Genome Variation and Clinical Utility
1:45 Chairperson’s Remarks
»»KEYNOTE PRESENTATION
1:50 Lessons from the Clinical Sequencing Exploratory
Research (CSER) Consortium: Genomic Medicine
Implementation
Gail P. Jarvik, M.D., Ph.D., Head, Division of Medical Genetics, Arno G. Motulsky Endowed Chair in Medicine and Professor, Medicine and Genome
Sciences, University of Washington Medical Center
Recent technologies have led to affordable genomic testing. However, implementation of genomic medicine faces many hurdles. The Clinical Sequencing Exploratory Research (CSER) Consortium, which includes nine genomic medicine projects, was formed to explore these challenges and opportunities. Dr. Jarvik is the PI of a CSER genomic medicine project and of the CSER coordinating center. She will focus on the frequency of exomic incidental findings, including those of the 56 genes recommended for incidental finding return by the ACMG. The CSER group has annotated the putatively pathogenic and novel variants of the Exome Variant Server (EVS) to estimate the rate of these in individuals of European and African ancestry. Experience with consenting and returning incidental findings will also be reviewed.
2:35 Decoding the Patient’s Genome: Clinical Use of Genome-Wide
Sequencing Data
Elizabeth Worthey, Ph.D., Assistant Professor, Pediatrics & Bioinformatics Program, Human & Molecular Genetics Center, Medical College of Wisconsin
Despite significant advances in our understanding of the genetic basis of disease, genomewide identification and subsequent interpretation of the molecular changes that lead to human disease represent the most significant challenges in modern human genetics.
Starting in 2009 at MCW, we have performed clinical WGS and WES to diagnose patients coming from across all clinical specialties. I will discuss findings, pros and cons in approach, challenges remaining and where we go next.
3:05 Analyzing Variants with a DTC Genetics Database
Brian Naughton, Ph.D., Founding Scientist, 23andMe, Inc.
Sequencing a genome results in dozens of potentially disease-causing variants (VUS). I describe some examples of using the 23andMe database, including quick recontact of participants, to determine if a variant is disease-causing.
3:35 Refreshment Break in the Exhibit Hall with Poster Viewing
Genome Interpretation Software Solutions: Software Spotlights
(Sponsorship Opportunities Available)
Obtaining clinical genome data is rapidly becoming a reality, but analyzing and interpreting the data remains a bottleneck. While there are many commercial software solutions and pipelines for managing raw genome sequence data, providing the medical interpretation and delivering a clinical diagnosis will be the critical step in fulfilling the promise of genomic medicine. This session will showcase how genome data analysis companies are streamlining the genomic diagnostic pipeline through:
• Transferring raw sequencing data
• Interpreting genetic variations
• Building new software and cloud-based analysis pipelines
• Investigating the genetic basis of disease or drug response
• Integrating with other clinical data systems
• Creating new medical-grade databases
• Reporting relevant clinical information in a physician-friendly manner
• Continuous learning feedback
4:15 Software Spotlight #1
4:30 Copy Number Variant Detection Using Sponsored by
Next-Generation Sequencing: State of the Art
Alexander Kaplun, Ph.D., Field Applications Scientist, BIOBASE
This talk will provide a short review about the current state of the art in detection of larger variants that have an important role in many diseases such as haplotypes, indels, repeats, copy number variants (CNVs), structural variants (SVs) and fusion genes using NGS methods, and an outlook to their use for pharmacogenomic genotyping.
4:45 Software Spotlight #3
5:00 Software Spotlight #4
5:15 Software Spotlight #5
5:30 Pertinence Metric Enables Hypothesis-Independent Sponsored by
Genome-Phenome Analysis in Seconds
Michael M. Segal, M.D., Ph.D., Chief Scientist, SimulConsult
Genome-phenome analysis combines processing of a genomic variant table and comparison of the patient’s findings to those of known diseases (“phenome”). In a study of 20 trios, accuracy was 100% when using trios with family-aware calling, and close to that if only probands were used. The gene pertinence metric calculated in the analysis was 99.9% for the causal genes. The analysis took seconds and was hypothesis-independent as to form of inheritance or number of causal genes. Similar benefits were found in gene discovery situations.
6:00 Welcome Reception in the Exhibit Hall with Poster Viewing
7:00 Close of Day
WEDNESDAY, JUNE 11
7:30 am Breakfast Presentation (Sponsorship Opportunity Available) or Morning Coffee
NGS Is Guiding Therapies
8:30 Chairperson’s Opening Remarks
8:35 Next-Generation Sequencing Approaches for Identifying Patients
Who May Benefit from PARP Inhibitor Therapy
Mitch Raponi, Ph.D., Senior Director and Head, Molecular Diagnostics, Clovis Oncology
The following questions will be addressed: What biomarkers should we be focusing on to identify appropriate patients who will likely benefit from PARP inhibitors? How can we apply next-generation sequencing technologies to identify all patients who will respond to the PARP inhibitor rucaparib? What regulatory challenges are we faced with for approval of NGS companion diagnostics?
9:05 Whole-Genome and Whole-Transcriptome Sequencing to Guide
Therapy for Patients with Advanced Cancer
Glen J. Weiss, M.D., MBA, Director, Clinical Research, Cancer Treatment Centers of America
Treating advanced cancer with agents that target a single-cell surface receptor, up-regulated or amplified gene product or mutated gene has met with some success; however, eventually the cancer progresses. We used next-generation sequencing technologies (NGS) including whole-genome sequencing (WGS), and where feasible, whole-transcriptome sequencing (WTS) to identify genomic events and associated expression changes in advanced cancer patients. While the initial effort was a slower process than anticipated due to a variety of issues, we demonstrated the feasibility of using NGS in advanced cancer patients so that treatments for patients with progressing tumors may be improved. This lecture will highlight some of these challenges and where we are today in bringing NGS to patients.
9:35 The SmartChip TE™ Target Enrichment System for Sponsored by
Clinical Next-Gen Sequencing
Gianluca Roma, MS MBA, Director, Product Management, WaferGen Biosystems
10:05 Coffee Break in the Exhibit Hall with Poster Viewing
Data Mining
»»KEYNOTE PRESENTATION
10:45 Translating a Trillion Points of Data into
Therapies, Diagnostics and New Insights into Disease
Atul Butte, M.D., Ph.D., Division Chief and Associate Professor, Stanford University School of Medicine; Director, Center for Pediatric Bioinformatics,
Lucile Packard Children’s Hospital; Co-Founder, Personalis and Numedii
There is an urgent need to translate genome-era discoveries into clinical utility, but the difficulties in making bench-to-bedside translations have been well described. The nascent field of translational bioinformatics may help. Dr. Butte’s lab at Stanford builds and applies tools that convert more than a trillion points of molecular, clinical and epidemiological data— measured by researchers and clinicians over the past decade—into diagnostics, therapeutics and new insights into disease. Dr. Butte, a bioinformatician and pediatric endocrinologist, will highlight his lab’s work on using publicly available molecular measurements to find new uses for drugs, including drug repositioning for inflammatory bowel disease, discovering new treatable inflammatory mechanisms of disease in type 2 diabetes and the evaluation of patients presenting with whole genomes sequenced.
11:30 DGIdb – Mining the Druggable Genome
Malachi Griffith, Ph.D., Research Faculty, Genetics, The Genome Institute, Washington University School of Medicine
In the era of high-throughput genomics, investigators are frequently presented with lists of mutated or otherwise altered genes implicated in human disease. Numerous resources exist to generate hypotheses about how such genomic events might be targeted therapeutically or prioritized for drug development. The Drug-Gene Interaction database (DGIdb) mines these resources and provides an interface for searching lists of genes against a compendium of drug-gene interactions and potentially druggable genes. DGIdb can be accessed at dgidb.org.
12:00 pm Sponsored Presentation (Opportunity Available)
12:30 Luncheon Presentation (Sponsorship Opportunity Available)
The unstoppable march of genomics into clinical practice continues. In an ideal world, the expanding use of genomic tools will identify disease before the onset of clinical symptoms and determine individualized drug treatment leading to precision medicine. However, many challenges remain for the successful translation of genomic knowledge and technologies into health advances and clinical practice.
Bio-IT World and Cambridge Healthtech Institute are again proud to host the Third Annual TCGC: The Clinical Genome Conference, inviting stakeholders from all arenas impacting clinical genomics to share new findings and solutions for advancing the application of clinical genome medicine.
TCGC brings together many constituencies for frank and vital discussion of the applications, questions and solutions surrounding clinical genome analysis, including scientists, physicians, diagnosticians, genetic counselors, bioinformaticists, ethicists, regulators, insurers, lawyers and administrators.
Topics addressing successful translation of genomic knowledge and technologies into advancement of clinical utility (medicines and diagnostics) include but are not limited to:
Scientific Investigation and Interpretation
- Technologies/Platforms
- WGS/Exome/Single-Cell Sequencing
- Drug and Diagnostic Targets
- Interpretation and Analysis Pipelines
- Case Studies
Clinical Integration and Implementation
- Mechanisms to Monitor Genomic Medicine
- Determining Clinical Utility
- Standardization/Regulation/Certification
- Reimbursement
- Data Management
- Diagnostic Lab Infrastructure
- HIT/Data Integration
- Reporting Results to Patients/Physicians
Call for Speakers
For a limited time, we are inviting researchers and clinicians applying genome analysis tools in clinical settings, as well as regulators and administrators implementing genomics into the clinic, to submit proposals for platform presentations. Please note that due to limited speaking slots, preference is given to abstracts from those within pharmaceutical and biopharmaceutical companies, regulators and those from academic centers. Additionally, as per CHI policy, a select number of vendors/consultants who provide products and services to these genomic researchers are offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.
All proposals are subject to review by the organizers and Scientific Advisory Committee.
Please click here to submit a proposal.
Submission deadline for priority consideration: November 15, 2013
For more details on the conference, please contact:
Mary Ann Brown
Executive Director, Conferences
Cambridge Healthtech Institute
250 First Avenue, Suite 300
Needham, MA 02494
T: 781-972-5497
E: mabrown@healthtech.com
For exhibit and sponsorship opportunities, please contact:
Jay Mulhern
Manager, Business Development, Conferences & Media
Cambridge Healthtech Institute
250 First Avenue, Suite 300
Needham, MA 02494
T: 781-972-1359
E: jmulhern@healthtech.com
SOURCE
http://www.clinicalgenomeconference.com/
Like this:
Like Loading...
Read Full Post »